N/A N=197 The Skin Savvy Study: A Behavioral Skin Cancer Prevention Intervention
Skin Cancer Prevention
Primary: Sun Stage of Change at 3 Months — 17; 5; 10; 12 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=60 Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents
HIV
Primary: Incidence of Treatment-Emergent Serious Adverse Events — 4.0; 0 percentage of participants
Phase 4 N=545 A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure
HIV-1 Infection
Primary: Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 48 Weeks — 0.64; 0.44; 0.88; 0.88 proportion of participants
Phase 3 N=858 Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil
Alzheimer's Disease
Primary: Change in Cognition — 0.64; 0.55; 1.27 units on a scale — p=1.000
Phase 2 N=24 A Study to Evaluate the Effect of GW870086X on Allergen Challenge in Mild Asthmatics
Asthma
Primary: Late Asthmatic Response (LAR): Minimum FEV1 Between 4-10 Hours After Allergen Challenge on Day 13 of Each Treatment Period — -0.903; -0.663; -0.638; -0.446 Liters
Phase 3 N=665 Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine
Opioid Dependence · Opioid Related Disorders
Primary: Cumulative Distribution Function (CDF) of the Percentage of Urine Samples Negative for Opioids Combined With Self-Reports Negative for Illicit Opioid Use Collected From…
Phase 3 N=687 Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection
Chronic HCV Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 95.5; 100; 100; 94.2 percentage of participants
Phase 3 N=56 Intra-Articular Injections of Platelet-Rich Plasma in Knee Osteoarthritis: Unique Application Versus Triple Application
Osteoarthritis
Primary: Change in the Western Ontario and McMaster Universities (WOMAC) Ostearthritis Index (Therapeutic Effect) — 28.53; 22.27 units on a scale
Phase 4 N=13 A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy
ALLERGIC ASTHMA
Primary: Number of Participants With Change in Sputum Markers by End of Study — 0; 0 Participants
N/A N=1,001 Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study
Acute Decompensated Heart Failure · Acute Kidney Injury
Primary: Evaluating the Efficacy of the Triage NGAL Test as an Aid to Diagnosis of Acute Kidney Injury (AKI) in Patients Admitted to the Hospital With Symptoms of Acute Heart…
Phase 3 N=397 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c (Glycosylated Haemoglobin) — -1.45; -1.85; -0.09 percentage of glycosylated hemoglobin — p=< 0.0001
Phase 4 N=139 Antidepressant Treatment at an Inner City Asthma Clinic
Depression · Asthma
Primary: Asthma Control Questionnaire (ACQ) — 1.15; 1.63; 1.39; 1.23 units on a scale
N/A N=2,009 XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan
Angina · Chronic Coronary Occlusion · Stent Thrombosis
Primary: Number of Participants With Stent Thrombosis (ST) as Per ARC Definition — 6; 2; 6 participants
Phase 4 N=76 PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIV
HIV
Primary: Median Percentage of CD4 Positive T-Cells — 62; 70; 58; 66 percentage positive T-cells
Phase 2 N=44 Effect of Varenicline on Fixed-Dose Alcohol Administration in Participants With Alcohol Use Disorders
Alcohol Reactivity
Primary: Cognitive Function as Measured by Omissions on the CPT — 1.78; 1.28; 4.76; 0.98 Number of Omissions